e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Disease control and quality of life in airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: A useful physiological marker for evaluating the effect of indacaterol in COPD patients.
Y. Okada, Y. Kono, S. Soeda, H. Hara, K. Araki, M. To, Y. To (Tokyo, Koshigaya, Japan)
Source:
Annual Congress 2013 –Disease control and quality of life in airway diseases
Session:
Disease control and quality of life in airway diseases
Session type:
Thematic Poster Session
Number:
807
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Okada, Y. Kono, S. Soeda, H. Hara, K. Araki, M. To, Y. To (Tokyo, Koshigaya, Japan). LATE-BREAKING ABSTRACT: A useful physiological marker for evaluating the effect of indacaterol in COPD patients.. Eur Respir J 2013; 42: Suppl. 57, 807
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
LATE-BREAKING ABSTRACT: An algorithm for the identification of clinical COPD phenotypes in daily practice
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
LATE-BREAKING ABSTRACT: Stratification of patients with COPD by frequence of exacerbations is an essential step for what to treat in COPD. - A survey in a real life COPD population
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Longitudinal changes in COPD patients in primary care
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
LATE-BREAKING ABSTRACT: Usefulness of daily physical activity for monitoring therapeutic response in COPD
Source: Annual Congress 2013 –New physiologic boundaries
Year: 2013
Reduction in clinically important deterioration in COPD with aclidinium/formoterol
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Change in the COPD assessment test (CAT) score as predictor of short-term evolution of patients admitted for an exacerbation of COPD
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
LATE-BREAKING ABSTRACT: The prevalence of night and morning symptoms in primary care COPD patients: How do they relate to COPD health status and disease severity? An UNLOCK study
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015
Short-term evaluation of a remote patient support program in patients with COPD and frequent exacerbations. ESOPO study
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015
LATE-BREAKING ABSTRACT: Antioxidant supplementation in chronic obstructive pulmonary disease (COPD): A relevant way to optimize pulmonary rehabilitation effects
Source: International Congress 2016 – Latest insights into functional capacity and muscle weakness in chronic lung diseases
Year: 2016
LATE-BREAKING ABSTRACT: The effect of beta2-agonist on lung clearance index in COPD patients
Source: International Congress 2015 – Lung function: new findings and approaches
Year: 2015
LATE-BREAKING ABSTRACT: Cost-effectiveness of the LABA/LAMA dual bronchodilator QVA149 in a Swedish setting
Source: Annual Congress 2013 –Health economics of airway diseases
Year: 2013
Modelling the long-term effects of an active case finding programme for undiagnosed COPD
Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD
Year: 2016
LATE-BREAKING ABSTRACT: Validation of the DECAF score to predict hospital mortality in exacerbations of COPD
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
LATE-BREAKING ABSTRACT: Intra-day symptoms fluctuations: STORICO, observational study on the characterization of 24-hour symptoms in COPD patients
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016
Impact of lung function impairment and exacerbation history on COPD patient-reported utility
Source: International Congress 2014 – COPD markers
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept